Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon receptor expression in multiple sclerosis patients.

Begoña Oliver1, Cristobalina Mayorga, Victoria Fernández

  • 1Research Laboratory, Carlos Haya Hospital, Málaga, Spain.

Journal of Neuroimmunology
|December 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetic nanoparticles enable clinically relevant <i>in vitro</i> diagnosis of β-lactam allergy.

Materials today. Bio·2026
Same author

Editorial: New vaccines and drugs for human microbial infections.

Frontiers in microbiology·2026
Same author

Successful Application of the Mast Cell Activation Test in Immediate Hypersensitivity to Amoxicillin.

Allergy·2026
Same author

Dendrimeric Antigens for Passive Mast Cell Activation in the Evaluation of Amoxicillin Allergy.

Allergy·2026
Same author

Updated Treatment of Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report.

Allergy·2026
Same author

An mRNA-delivered consensus allergen induces a neutralizing IgG response against food and pollen allergens.

Nature communications·2026
Same journal

Methodological concerns in the cutoff determination of a flow cytometric MOG-IgG assay: The need for independent validation.

Journal of neuroimmunology·2026
Same journal

Clinical features, imaging findings, and treatment outcomes of optic neuritis associated with anti-CRMP5 antibodies: a systematic review.

Journal of neuroimmunology·2026
Same journal

Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.

Journal of neuroimmunology·2026
Same journal

Neurological sequelae of Long COVID: Pathophysiological mechanisms, diagnostic advances, and therapeutic perspectives.

Journal of neuroimmunology·2026
Same journal

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same journal

Clinical characteristics of IgG4-related hypertrophic pachymeningitis with and without serum ANCA positivity.

Journal of neuroimmunology·2026
See all related articles

Interferon-beta (IFNbeta) treatment in multiple sclerosis (MS) patients down-regulates IFNAR1 and IFNAR2 receptor expression. This gene expression change is more pronounced in patients responding well to IFNbeta therapy.

Area of Science:

  • Immunology
  • Neuroscience
  • Genetics

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon-beta (IFNbeta) is a common therapeutic agent for MS, but its precise mechanism of action and response predictors are still under investigation.
  • Understanding gene expression patterns related to IFNbeta treatment can provide insights into therapeutic efficacy.

Purpose of the Study:

  • To investigate the gene expression of Interferon Alpha/Beta Receptor 1 (IFNAR1) and Interferon Alpha/Beta Receptor 2 (IFNAR2) and Myxovirus Resistance Protein A (MxA) in MS patients undergoing IFNbeta therapy.
  • To determine the association between these gene expression levels and the clinical response to IFNbeta treatment in MS patients.

Main Methods:

  • Gene expression analysis of IFNAR1, IFNAR2, and MxA was performed on samples from MS patients treated with IFNbeta, untreated MS patients, and healthy controls.

Related Experiment Videos

  • Comparison of gene expression levels between treatment responders and non-responders was conducted.

    • Main Results:

    • MS patients treated with IFNbeta showed a significant decrease in IFNAR1 and IFNAR2 expression and a significant increase in MxA expression compared to non-treated patients and healthy controls.
    • Patients with a good response to IFNbeta treatment exhibited a significantly greater decrease in IFNAR1 and IFNAR2 expression compared to non-responders, untreated patients, and healthy controls.
    • IFNbeta treatment appears to influence its own receptor expression, with greater down-regulation observed in treatment responders.

    Conclusions:

    • IFNbeta treatment significantly alters the gene expression of its receptors (IFNAR1, IFNAR2) and an interferon-stimulated gene (MxA) in MS patients.
    • The down-regulation of IFNAR1 and IFNAR2 expression is significantly associated with a positive clinical response to IFNbeta therapy in MS.
    • This observed down-regulation of IFNbeta receptors may serve as a potential biomarker for predicting or indicating treatment response in MS.